Sonoma Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Sonoma Pharmaceuticals

06/02/2025 22:01

* Sonoma Pharmaceuticals Inc  SNOA.OQ  reported a quarterly
adjusted loss of 63 cents​​ per share for the quarter ended
December 31, higher than the same quarter last year, when the
company reported EPS of $-1.60.  The lone analyst forecast for
the quarter was for a loss of 69 cents per share. 
    * Revenue rose 13.6% to $3.56 million from a year ago;
analysts
expected $4.06 million. 
    * Sonoma Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 63 cents​.
    * The company reported a quarterly loss of $928 thousand.
    * Sonoma Pharmaceuticals Inc shares had fallen by 1.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 13.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "strong buy"

Wall Street's median 12-month price target for Sonoma
Pharmaceuticals Inc is $17.00 
This summary was machine generated from LSEG data February 6 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.69          -0.63          Beat
 Sep. 30 2024      -1.00          -0.59          Beat
 Jun. 30 2024      -1.20          -1.40          Missed
                                  -1.39